Blueprint Medicines Corp at Goldman Sachs Healthcare Conference Transcript
Good morning. Thanks, everyone, for joining us. I'm Salveen Richter, biotechnology analyst at Goldman Sachs, and we're really pleased to have the Blueprint team with us. We have Kate Haviland, CEO; and Fouad Namouni, President of R&D. So Kate, maybe to start with you here. Since assuming the role of CEO, have you implemented any changes in strategy? And how are you thinking of where Blueprint goes on the forward from here?
Yes. So first of all, thank you, Salveen, and the whole Goldman Sachs team for having us here today. It's great to see a bunch of people in the room, and those of us on the webcast, thank you for joining.
It's -- Blueprint, I have joined Blueprint Medicines almost 7.5 years ago. And we started out as a company that had very important but very discrete precision medicine opportunities with our first approval being PDGFR alpha-driven GIST for AVYAKIT in 2020. And where we are
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
